Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wenhong Zhang, PHD
…l to evaluate the efficacy and safety of seven 9-month oral regimens compared to a 9-month standard of care (SOC) regimen in RR-TB participants susceptible to fluoroquinolones, and a bedaquiline-containing 9-month oral regimen compared to a 20-month conventional regimen in RR-TB …
Rashmi Ratnam, Parul Jain, Ram Awadh Singh Kushwaha, Amita Jain, Urmila Singh, et al.
…the World Health Organization (WHO) recommends two all-oral regimens for rifampicin-resistant (RR), multidrug-resistant (MDR), and extensively drug-resistant (XDR) TB: a longer M/XDR-TB regimen (18–20 months) and a shorter bedaquiline-containing MDR/RR-TB regimen (9–11 months). T…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Thi Mai Phuong Nguyen, Van Luong Dinh, Binh Hoa Nguyen, Thi Thanh Thuy Hoang, Viet Nhung Nguyen, et al.
…in-resistant TB (RR-TB) burden country. Different new RR-TB regimens were recommended in recent years. Locally-generated evidence about nationwide implementation of different RR-TB regimens is essential to inform national treatment guidelines. **METHODS:** A retrospective cohort…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Gunar Günther, Lorenzo Guglielmetti, Claude Leu, Christoph Lange, Frank van Leth, et al.
…berculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region. Results are stratified by middle and high-income countries. Results Overall, 43 treatment centers in 4…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…eatment failure, and loss of follow-up) related to all oral regimens containing bedaquiline and or delamanid in patients with MDR-TB. Method: This was a narrative review to summarize the role of the BPaL regimen to manage highly DR-TB patients. Results: The six months of BPaL reg…
Rashmi Ratnam, Roli Kushwaha, Parul Jain, Amita Jain
…tuberculosis (DR-TB), introduced two bedaquiline-containing regimens endorsed by the WHO for Rifampicin-resistant/Multi-drug resistant tuberculosis (RR/MDR TB). This study assesses clinical and microbiological outcomes of these regimens in RR/MDR TB patients. <bold>Material & Met…
Shuang Wei, M.D.
… is an urgent need for new, effective and safe short-course regimens for drug-resistant tuberculosis. A 6-month short-course oral regimen containing pretomanid was introduced in 2020. However, as pretomanid is not yet available in China, it has not been verified and promoted in C…
Padmapriyadarsini Chandrasekharan
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models o…
Sha wei
…e public health burden.Research on optimal drug combination regimens to further shorten the duration and improve the efficacy of multidrug-resistant tuberculosis treatment is an important research direction.The PRS (parabolic response surface, FSC.II) system is an enhanced use of…
Yu. I. Feshchenko, N.А. Lytvynenko, M.V. Pohrebna, Yu.О. Senko, Anastasiia Lafeta, et al.
Objective — to study the programmatic results of the efficacy and tolerability of the standard combination BPaL regimen for patients with multidrug-resistant tuberculosis failures and pre-XDR-TB. Materials and methods. Treatment of patients with BPaL regimen took place within th…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
… of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (B…
Pankaj Jorwal, Anivita Aggarwal, Parul Kodan, Nitin Gupta, Sudeshna Ghosh, et al.
…e difficulty in its diagnosis, the long course of treatment regimens is associated with multiple side-effects, poor compliance and undesirable rate of a positive outcome. Before the availability of newer treatment regimens and newer drugs, positive outcomes in patients with XDR-T…
Mutong Fang, Sinian Li, Xiangxiang Liu, Guoju Shao, Zhi Mao, et al.
…ety between bedaquiline(Bdq) and non-bedaquiline containing regimens for treatment of Pre XDR-TB. Meanwhile, we analyze the outcomes among different Bdq duration and total regimen duration. P < 0.05 is significantly different, GraphPad prism 5.0 software package was used to pr…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
In the recent manuscript by Günther G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Tri…
Vincent M. Balanag, Vivian Lofranco, Mariquita J. Mantala, Mary Rosary T. Santiago, Patrice Jamie E. Cabasis, et al.
… have shown the potential benefits of adding bedaquiline to regimens for drug-resistant TB (DR-TB). In search of more effective regimens for DR-TB, bedaquiline was introduced in the TB program in the Philippines under operational research to assess its effectiveness, safety, and …
Silviа Borisova, Н. Б. Бородина
…tered concurrently with antiretroviral therapy in treatment regimens for patients with such comorbidities as HIV infection and multiple drug resistant and extensively drug resistant tuberculosis. Subjects and Methods. Effectiveness and safety of chemotherapy regimens containing b…
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, et al.
… medical patient costs were negligible across all treatment regimens, while direct non-medical patient and guardian costs for travel, food and nutritional supplementation accounted for the largest proportion of total costs ($54.6, $227.8 and $224.3 for BPaL, the SSOR and SLOR res…
Animesh Sinha, Roland Klebe, Michael L Rekart, Jose Luis Alvarez, Alena Skrahina, et al.
…ll-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings. **METH…
Fu L, Zhang X, Xiong J, Sun F, Weng T, et al.
Objectives Long, ineffective, and toxic regimens hinder the treatment of patients with multidrug-resistant tuberculosis (MDR-TB) and pre-extensive drug-resistant tuberculosis (pre-XDR-TB). Methods We conducted a multicenter cohort study to prospectively evaluate the safety and ef…
Philipp du Cros, MBBS, Khamraev A Karimovich, MD
…veral countries in West Africa started implementing similar regimens with similar outcomes. Evidence of effectiveness of this shortened regimen among regions with high second line drug use and resistance is still limited. The investigators propose an observational study under pr…
А. V. Kukurika
…ively drug-resistant tuberculosis (MDR/XDR-TB) chemotherapy regimens. Material and methods. An analysis of 19 publications devoted to the economic evaluation of the treatment of active MDR/XDR-TB was carried out. The literature search was performed in the electronic databases Pub…
Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, et al.
…ess and safety of bedaquiline (BDQ)-containing and BDQ-free regimens for treatment of patients with refractory RR/MDR/XDR-TB. Methods Patients with refractory RR/MDR/XDR-TB receiving BDQ-containing regimens (BDQ group, n = 102) and BDQ-free regimens (non-BDQ group, n = 100) satis…
van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, et al.
…ernative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. …